Pharmaceutical and Device Industry Outlook -

Health Industry Forum January 10, 2013

Kathy Buto VP Global Health Policy January 10, 2013

Biggest Overall Impact of Current Environment

- Uncertainty short- and long-term business and healthcare environment
- Sequential budget crises in U.S., disproportionate cuts
- Restructuring and consolidation of healthcare system
- Larger entitlement reform may follow but with significant savings taken out first
- Concern about U.S. corporate tax system
- ACA important but uncertainty and short-term focus is a bigger problem

Biopharmaceuticals

- Unmet medical need Alzheimers, diabetes, cancer, multi-drug resistant TB, Hep C – balancing developed and developing country needs
- Difficult regulatory environment
 - Biosimilars pathway
 - Personalized medicine
 - e.g., type 2 diabetes drugs, additional reqs for CV effects, in absence of safety signals
- ACOs
 - Engaged in discussions, not clear role
 - Part B drugs count, Part D drugs don't
 - Concern if tech/Tx not in baseline (Alzheimers treatments)
 - Continued demand for better evidence of outcomes
- Reimbursement challenges
 - Continued target for cuts most concern about Part D rebates
 - Coverage limits

Medical Devices

- Regulatory environment difficult, esp for combination products
- ACOs
 - Engaging, not clear role
 - Greater commoditization of products by providers, including ACOs, demand for better evidence of value
 - Opportunities to develop broader solutions, e.g., geriatric fracture program

Partnerships, New Opportunities

- Challenge as providers and insurers develop new partnerships
 - role we can plan in management of care
 - connectivity of patients & physicians
 - "with the grain" solutions that will improve quality, reduce costs (HAIs, post-operative recovery, prevention & wellness)
- Convergence of business around conditions and patient need – continuum from prevention to consumer ed, management around treatment, medication adherence, feedback to physicians, data capture